HereS a breakdown of the key takeaways from the provided article, focusing on the treatment of Thyroid Eye Disease (TED):
Key Points on Treating Thyroid Eye Disease (TED):
* Initial Assessment: The first priority is to assess for visual compromise (optic neuropathy, exposure keratopathy) and then look for signs of inflammation.
* VISA Scale: The VISA (likely an acronym for a specific inflammation assessment) system is used to track inflammation levels on a 10-point scale. A score of 6 or higher may indicate a need for more advanced therapy. It helps quickly classify the patient’s condition and understand the level of inflammation without immediate visual threat.
* “Big Three” Modifiable Risk Factors:
* Smoking Cessation: Absolutely crucial.
* Endocrine Management: Stabilizing thyroid hormone levels is vital. Avoid cycling between hyperthyroidism and hypothyroidism. Collaboration with endocrinologists is important.
* Avoid Radioactive Iodine: Should be avoided while the disease is active.
* Severe Cases – Thyroidectomy: For patients with severe, active TED, thyroidectomy (thyroid removal) is recommended as it can reduce the need for orbital decompression and the risk of optic neuropathy.
* Overall Approach: Managing these risk factors significantly improves patient outcomes.
Additional Facts:
* Source: The information was presented at Hawaiian Eye 2026 by Dr. Lucarelli.
* Disclosures: Dr. Lucarelli has research ties to Immunovant and sling Therapeutics.
